Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 11:05 ET | Source: BioNTX

BioNTX Concludes Landmark iC³® 2025 Summit — Announces 2026 Summit in Arlington, Texas

DALLAS, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The 2025 iC³® Life Science & Healthcare Innovation Summit, hosted by BioNTX, concluded on September 16–17 at the Hilton Anatole in Dallas, marking more...
December 01, 2025 10:08 ET | Source: Research and Markets

Iron Deficiency Anemia Therapy Market Trends, SWOT, Value Chain, Competition and Growth Analysis 2025-2030 - Nanomedicine Leads the Way in Therapeutic Advances

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Iron Deficiency Anemia Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ...
December 01, 2025 08:05 ET | Source: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind Announces U.S. FDA Accepts for Review its sNDA of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in adults with CHF or CKD
November 30, 2025 13:47 ET | Source: Timeline Auctions Ltd

TimeLine Auctions Announces 2 December Sale Featuring Masterpieces of Ancient Art, Fossils and Natural History

A Media Snippet accompanying this announcement is available by clicking on this link. HARWICH, United Kingdom, Nov. 30, 2025 (GLOBE NEWSWIRE) -- TimeLine Auctions will present an outstanding...
November 25, 2025 01:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...
November 20, 2025 07:00 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 ...
November 18, 2025 06:30 ET | Source: Custom Market Insights

[Latest] Global Yellow Phosphorus & Derivatives Market Size/Share Worth USD 9.02 Billion by 2034 at a 5.34% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Yellow Phosphorus & Derivatives Market Size, Trends and Insights By...
November 18, 2025 04:14 ET | Source: Research and Markets

Pharmaceuticals and Biotechnology Distribution Deals Trends Analysis Report 2025: Navigate Financial Terms and Payment Structures of Recent Distribution Deals

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Distribution Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering.The report contains a...
November 18, 2025 04:11 ET | Source: Research and Markets

Pharmaceuticals and Biotechnology Asset Purchase Agreements Analysis Report 2025: Everything a Prospective Dealmaker Needs to Know About Business, Product, Royalty, and Technology Assets

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2025" report has been added to ResearchAndMarkets.com's offering.The report provides...
November 18, 2025 04:09 ET | Source: Research and Markets

Pharmaceuticals Collaboration Agreements Analysis Report and Directory of Deals 2025: Track Trends, Benchmark Valuations, and Access Detailed Contract Terms from 2020 Onward

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Pharmaceuticals 2020-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of...